Elanco Animal Health (NYSE:ELAN – Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.160-0.190 for the period, compared to the consensus earnings per share estimate of 0.180. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.170-1.200 EPS.
Elanco Animal Health Price Performance
NYSE ELAN opened at $25.65 on Friday. Elanco Animal Health has a twelve month low of $19.40 and a twelve month high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock has a market capitalization of $12.81 billion, a PE ratio of -62.55, a P/E/G ratio of 2.14 and a beta of 1.73. The stock has a 50-day simple moving average of $23.13 and a 200 day simple moving average of $23.82.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the business posted $0.19 earnings per share. Elanco Animal Health’s quarterly revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Research analysts anticipate that Elanco Animal Health will post 1.13 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on ELAN
Insider Buying and Selling
In related news, insider Shiv O’Neill purchased 3,998 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were acquired at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Kurzius bought 40,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 48,998 shares of company stock worth $1,139,373. 1.14% of the stock is owned by company insiders.
Key Elanco Animal Health News
Here are the key news stories impacting Elanco Animal Health this week:
- Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
- Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
- Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
- Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.
The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.
Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.
Recommended Stories
- Five stocks we like better than Elanco Animal Health
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
